

Claim 37: Page 39, line 5.

Claims 38-43: Original claim 35; and page 39, line 10 to page 40, line 17.

Claims 44-45: Page 40, lines 18-21.

Claim 46: Page 29, line 30; see also, page 29, line 21 to page 33, line 4.

Claims 47-48: Page 38; page 39, line 5; page 40, lines 18-21; pages 58-59; and
original claim 35.


If the Examiner believes a telephone conference would expedite prosecution of this
application, please telephone the undersigned at 303-571-4000.

Respectfully submitted,



Scott L. Ausenhus
Reg. No. 42,271

TOWNSEND and TOWNSEND and CREW LLP
Two Embarcadero Center, 8th Floor
San Francisco, California 94111-3834
Tel: (303) 571-4000 (Denver)
Fax: (415) 576-0300
SLA
DE 7082857 v3



GOSLING et al.
Application No. 99/686,020
Page 6

RECEIVED

OCT 25 2002

PATENT

TECH CENTER 1600/2900

APPENDIX A

VERSION WITH MARKINGS TO SHOW CHANGES MADE

IN THE SPECIFICATION:

The title on page 1 has been amended as follows::

~~CHEMOKINE RECEPTOR~~

METHODS OF TREATING A CCX CKR-MEDIATED DISEASE

IN THE ABSTRACT:

The title in the abstract on page 65, line 2 has been amended as follows:

~~CHEMOKINE RECEPTOR~~

METHODS OF TREATING A CCX CKR-MEDIATED DISEASE

IN THE CLAIMS:


The following claims have been amended as indicated without prejudice or disclaimer:

33. (Amended) A method of treating an CCX CKR-mediated condition in a mammal comprising administering to the mammal an agent that ~~modulates the activity or expression of CCX-CKR~~ inhibits or promotes the binding of CCX CKR to ELC (EBI-1-ligand chemokine), SLC (secondary lymphoid organ chemokine) TECK (thymus expressed chemokine), BLC (B-lymphocyte chemoattractant), CTACK (cutaneous T cell attracting chemokine), mMIP-1 γ (murine macrophage inflammatory protein 1 γ), or vMIPII (viral macrophage inflammatory protein II) in a cell or tissue in the mammal.

34. (Amended) The method of claim 33, wherein the agent ~~is an agent that~~ inhibits the binding of CCX CKR to ELC, SLC, ~~or~~ TECK, BLC, CTACK, mMIP-1 γ or vMIPII.

35. (Amended) The method of claim 33, wherein the CCX CKR-mediated condition is selected from the group consisting of inflammation, an allergic disease ~~allergy~~, an autoimmune disease, graft rejection, cancer, an ~~ifectous~~ infectious disease or an immunosuppressive disease.

36. (Amended) The method of claim 35, wherein the CCX CKR-mediated condition is inflammation.



GOSLING
Application No.: 09/686,020
Page 8

RECEIVED

OCT 25 2002

PATENT

TECH CENTER 1600/2900

APPENDIX B

PENDING CLAIMS

1-32. Canceled.

33. (Amended) A method of treating an CCX CKR-mediated condition in a mammal comprising administering to the mammal an agent that inhibits or promotes the binding of CCX CKR to ELC (EBI-1-ligand chemokine), SLC (secondary lymphoid organ chemokine), TECK (thymus expressed chemokine), BLC (B-lymphocyte chemoattractant), CTACK (cutaneous T cell attracting chemokine), mMIP-1 γ (murine macrophage inflammatory protein 1 γ), or vMIPII (viral macrophage inflammatory protein II) in a cell or tissue in the mammal.

34. (Amended) The method of claim 33, wherein the agent inhibits the binding of CCX CKR to ELC, SLC, TECK, BLC, CTACK, mMIP-1 γ or vMIPII.

35. (Amended) The method of claim 33, wherein the CCX CKR-mediated condition is selected from the group consisting of inflammation, an allergic disease, an autoimmune disease, graft rejection, cancer, an infectious disease or an immunosuppressive disease.

36. (Amended) The method of claim 35, wherein the CCX CKR-mediated condition is inflammation.

37. (New) The method of claim 33, wherein the agent promotes the binding of CCX CKR to ELC, SLC TECK, BLC, CTACK, mMIP-1 γ , or vMIPII.

38. (New) The method of claim 35, wherein the CCX CKR-mediated condition is an allergic disease.

39. (New) The method of claim 35, wherein the CCX CKR-mediated condition is an autoimmune disease.

40. (New) The method of claim 35, wherein the CCX CKR-mediated condition is graft rejection.

41. (New) The method of claim 35, wherein the CCX CKR-mediated condition is cancer.

42. (New) The method of claim 35, wherein the CCX CKR-mediated condition is an infectious disease.

43. (New) The method of claim 35, wherein the CCX CKR-mediated condition is an immunosuppressive disease.

44. (New) The method of claim 33, wherein the mammal is a human.

45. (New) The method of claim 33, wherein the mammal is a non-human primate.

46. (New) The method of claim 33, wherein the agent is an antibody.

47. (New) The method of claim 34, wherein
the mammal is a human; and
the CCX CKR-mediated condition is selected from the group consisting of
inflammation, an allergic disease, an autoimmune disease, graft rejection, cancer, an
infectious disease or an immunosuppressive disease.

48. (New) The method of claim 37, wherein
the mammal is a human; and
the CCX CKR-mediated condition is selected from the group consisting of
inflammation, an allergic disease, an autoimmune disease, graft rejection, cancer, an
infectious disease or an immunosuppressive disease. --